New Treatments for Hashimoto's Thyroiditis (2026)

Thirty-five to forty percent of Hashimoto's patients on optimized levothyroxine still report significant symptoms. Fatigue, brain fog, weight gain, joint pain. Their TSH looks normal on paper. The autoimmune attack on their thyroid continues unchecked.

Standard care replaces the hormone your damaged thyroid can no longer produce. It does not address why your immune system is destroying it. That gap between hormone replacement and immune management is where the most promising new treatments operate.

This is a 2026 evidence update. Every treatment below carries an evidence grade: Grade B means clinical trial data or strong mechanistic evidence supports it. Grade C means the data is preliminary or preclinical. None of these replace levothyroxine or standard endocrine care. All should be discussed with your physician before starting.

This site provides educational information only. Not medical advice. Always consult your healthcare provider before changing your treatment plan.

Why Standard Treatment Leaves Many Patients Unsatisfied

Levothyroxine is synthetic T4. It normalizes TSH. For many patients, that is enough.

For a large subset, it is not. The reasons are becoming clearer.

The autoimmune component goes unaddressed. Levothyroxine replaces thyroid hormone. It does nothing to slow or stop the lymphocytic infiltration destroying thyroid tissue. TPO antibody levels, the marker of ongoing immune activity, are rarely monitored aggressively after diagnosis.

Poor T4-to-T3 conversion affects a genetic subset. The DIO2 gene encodes the enzyme that converts T4 (inactive storage hormone) into T3 (the active form your cells use). A common polymorphism (Thr92Ala) impairs this conversion. Patients carrying this variant may have normal TSH and free T4 but inadequate tissue-level T3 (Panicker et al. 2009, BMJ). T4-only therapy cannot solve a conversion problem.

Symptom persistence is well documented. Leese et al. (2019, BMJ Open) found that 35-40% of patients on levothyroxine reported significant residual symptoms despite biochemically normal thyroid function. This is not a fringe complaint. It is a documented treatment gap.

The emerging consensus among thyroid researchers: replacing the hormone deficit is necessary. It is not sufficient for all patients.

What You Can Do Now: Evidence-Supported Options

These treatments have clinical trial data or strong mechanistic plus clinical evidence. All carry a Grade B evidence rating for Hashimoto's. Discuss each with your endocrinologist before starting.

Low-Dose Naltrexone (LDN): Grade B

Low-dose naltrexone works by transiently blocking opioid receptors at bedtime, which triggers a rebound upregulation of endogenous opioids (particularly OGF, opioid growth factor). This cascade enhances regulatory T cells (Tregs), the immune cells responsible for preventing autoimmune attacks.

LDN also antagonizes TLR4 (toll-like receptor 4), a key driver of the inflammatory cascade in Hashimoto's thyroid tissue. TLR4 is overexpressed on thyrocytes and infiltrating lymphocytes in Hashimoto's glands.

The Hashimoto's-specific evidence is observational: case series data and patient registry reports from the LDN Research Trust showing TPO antibody reductions and symptom improvement. No completed RCT targeting thyroid autoimmunity as a primary endpoint exists. The broader autoimmune evidence is stronger, with completed trials in fibromyalgia (Younger et al. 2013), Crohn's disease (Smith et al. 2007), and MS.

Practical details: Off-label. Requires a compounding pharmacy. Typical protocol starts at 1.5mg at bedtime, titrating to 4.5mg over 8-12 weeks. Cost runs $40-80 per 90-day supply. Absolute contraindication: concurrent opioid medications.

For the full protocol, see our LDN for Hashimoto's guide and the broader LDN for autoimmune disease overview.

Metformin: Grade B

This may be the most underreported development in Hashimoto's management. Metformin, a diabetes drug prescribed for over 60 years, has accumulated 17+ studies examining its effects on thyroid autoimmunity.

The mechanism centers on AMPK activation. Metformin activates AMP-activated protein kinase, which suppresses mTOR signaling. The downstream effect: downregulation of Th17 cells (pro-inflammatory) and upregulation of Tregs (anti-inflammatory). This shifts the immune balance away from autoimmune attack.

Key evidence:

• Guo et al. 2023 (meta-analysis, Journal of Clinical Endocrinology & Metabolism, n=700+): metformin significantly reduced both TPO antibodies and thyroglobulin antibodies compared to control groups.
• Krysiak et al. 2015 (British Journal of Pharmacology): in women with Hashimoto's and insulin resistance, metformin significantly reduced TPO-Ab and TG-Ab beyond what levothyroxine achieved alone.
• Multiple studies show TSH reduction in subclinical hypothyroidism, suggesting a thyroid-protective effect independent of glucose control.

Practical details: Off-label for non-diabetic Hashimoto's patients. Typical dose: 500-1000mg daily. Requires a prescribing physician. Well-established safety profile over six decades of clinical use. GI side effects (nausea, diarrhea) are common, particularly at initiation. Extended-release formulations reduce GI burden. Contraindicated in significant renal impairment (check eGFR).

Selenium + Myo-Inositol Combination: Grade B

Both selenium and myo-inositol have independent RCT evidence for Hashimoto's. The combination appears to produce additive benefits that exceed either supplement alone.

Nordio and Basciani (2017) conducted a 6-month RCT comparing selenium 83mcg plus myo-inositol 600mg against selenium alone. TSH normalized in 31% more patients in the combination group. TPO antibody reduction was significantly greater with the combination. Zuhair et al. (2024) replicated these findings.

The mechanism is complementary. Selenium is required for glutathione peroxidase activity in thyroid tissue, protecting against oxidative damage during hormone synthesis. Myo-inositol is a TSH signaling mediator: it acts as a second messenger in the TSH receptor pathway, improving thyroid hormone production efficiency.

Practical details: Over-the-counter. Selenomethionine 100-200mcg daily (do not exceed 200mcg; selenosis risk at higher doses). Myo-inositol 600mg twice daily. Both are widely available and inexpensive.

For detailed dosing protocols, see selenium for Hashimoto's and myo-inositol for Hashimoto's.

T3/T4 Combination Therapy: Grade B

Standard of care prescribes T4 only (levothyroxine). For patients with the DIO2 Thr92Ala polymorphism or persistent symptoms despite normal TSH, adding T3 (liothyronine) addresses the conversion bottleneck directly.

Adthyza, an FDA-approved fixed-dose combination of levothyroxine and liothyronine, reached the market in 2023. Before Adthyza, combination therapy required two separate prescriptions and careful dose titration. The fixed-dose tablet simplifies this considerably.

Idrees et al. (2023, meta-analysis) found that T4+T3 combination improved mood, quality of life, and cognitive function compared to T4 alone in a subset of patients. The effect size was modest. Not every patient benefits; those with normal DIO2 function and adequate T3 levels may see no improvement.

Practical details: Prescription required. Adthyza simplifies dosing but is more expensive than generic levothyroxine. Discuss DIO2 testing with your endocrinologist to determine if you are a candidate. Optimal lab ranges for Hashimoto's can help you evaluate whether your T3 levels suggest a conversion issue.

Fasting Mimicking Diet (FMD): Grade B

Valter Longo's research at USC demonstrated that cycles of caloric restriction trigger immune system regeneration. During fasting, the body depletes old and damaged lymphocytes. During refeeding, hematopoietic stem cells regenerate a fresh immune repertoire with a more favorable Treg-to-effector ratio.

Choi et al. (2016) demonstrated reduced autoimmune markers in an MS mouse model and pilot human data. A 2026 RCT published in Nature Medicine showed significant benefit in Crohn's disease. No Hashimoto's-specific RCT exists, but the mechanistic rationale is strong: if you can reset the immune cells attacking your thyroid, antibody levels should fall.

The standard protocol uses ProLon, a 5-day plant-based kit providing 800-1,100 calories per day (low protein, low carb). Typical approach: monthly for 3 cycles, then quarterly for maintenance.

Practical details: Self-directed or kit-based (ProLon ~$200 per cycle). Not appropriate for underweight patients, those with eating disorder history, or pregnant/nursing women. Discuss with your physician, particularly regarding medication timing during fasting days.

For a deeper look at the evidence, see fasting mimicking diet for autoimmune disease.

Emerging Treatments: Early Data, Worth Watching

These have preliminary or small-study data. Grade C evidence: promising signals, not yet actionable for most patients. Track them. Do not build a treatment plan around them yet.

Red Light Therapy (Photobiomodulation): Grade C

Near-infrared light at 630-850nm wavelengths penetrates thyroid tissue and activates cytochrome c oxidase in the mitochondrial electron transport chain. This increases ATP production and reduces local inflammatory markers.

Höfling et al. (2012, Lasers in Surgery and Medicine, n=43 RCT) applied near-infrared laser directly to the thyroid over 10 sessions. Results: 47% of treated patients reduced their levothyroxine dose versus none in the control group. Ultrasound showed improved thyroid echogenicity, suggesting reduced lymphocytic infiltration.

Ferreira et al. (2025, MDPI Photonics) reviewed 8 studies including 3 RCTs. The signal is consistent: TPO antibody reduction and reduced medication requirements. Sample sizes remain small and methodological quality is mixed.

Practical reality: Not widely available. Some functional medicine practices offer professional-grade photobiomodulation. Consumer red light panels have not been validated for thyroid application. The thyroid is highly vascular; professional administration to the correct thyroid area matters.

Gut Microbiome Targeted Therapies: Grade C

The gut-thyroid axis is real. Knezevic et al. (2020, Thyroid) documented consistent gut dysbiosis in Hashimoto's patients compared to healthy controls. Specific patterns include reduced Lactobacillus and Bifidobacterium species and increased inflammatory taxa.

Preliminary data on specific probiotic strains (Lactobacillus reuteri, Bifidobacterium longum) show TPO antibody modulation in small studies. Prebiotic fiber (resistant starch, inulin) supports short-chain fatty acid production, particularly butyrate, which enhances Treg function in the gut-associated lymphoid tissue.

Fecal microbiota transplant (FMT) has shown promise in inflammatory bowel disease but has no Hashimoto's trial data. The theoretical rationale is sound; the clinical evidence is not yet there.

Practical reality: Probiotics and prebiotic fiber are low-risk interventions that may provide modest benefit. Targeted microbiome therapies for Hashimoto's are years from clinical validation.

See the probiotics section in best supplements for autoimmune disease for current evidence.

Rituximab and B-Cell Depletion: Grade C

Rituximab (anti-CD20 monoclonal antibody) depletes B cells, which reduces autoantibody production. It is FDA-approved for severe RA and lupus.

In Hashimoto's, small case series (reviewed by Hasham and Tomer, 2012) show TPO antibody reduction following rituximab infusion. No RCT exists. The risk profile is significant: broad immunosuppression, infusion reactions, and a small risk of progressive multifocal leukoencephalopathy (PML).

Practical reality: Not appropriate for uncomplicated Hashimoto's. The risk-benefit ratio does not support its use when the condition is manageable with hormone replacement and the interventions listed above. Relevant only for severe refractory cases or Hashimoto's encephalopathy, where the autoimmune component causes neurological damage.

Weekly Injectable Levothyroxine: Grade C

Compliance is a real problem with daily oral levothyroxine. The drug must be taken on an empty stomach, 30-60 minutes before food, separated from iron, calcium, and magnesium supplements. Coffee impairs absorption. Gastric bypass patients absorb it poorly.

Cappelli et al. (2021, Journal of Clinical Endocrinology & Metabolism) tested weekly intramuscular levothyroxine in a Phase II trial and found it non-inferior to daily oral dosing for TSH control. The approach bypasses all absorption issues.

Practical reality: No FDA-approved product exists. No commercial formulation is available. This remains in the development pipeline. Worth watching for patients with severe absorption problems or adherence challenges.

Can Hashimoto's Be Cured? Can It Go Into Remission?

Hashimoto's cannot currently be "cured" in the sense of permanently switching off the autoimmune mechanism. No treatment eliminates the genetic predisposition or guarantees that TPO antibodies will never return.

Remission, however, is documented and achievable.

Spontaneous remission occurs in 5-20% of patients without specific intervention (Premawardhana et al. 2006). Post-pregnancy remission is well documented: some women see significant TPO antibody reductions after delivery as the immune system rebalances.

Treatment-induced remission has been observed in small trials and clinical practice. The selenium plus myo-inositol combination normalized TPO antibodies in a meaningful subset of patients (Nordio and Basciani, 2017). AIP diet interventions (Abbott et al. 2019) produced significant symptom reduction and, in some cases, antibody normalization.

What remission looks like in practice: TSH stable within the normal range (ideally without medication, though many patients still require a reduced dose), TPO antibodies declining or within the reference range, and resolution of the fatigue, brain fog, and other symptoms that drove the patient to seek treatment.

What changes the trajectory: early intervention before extensive gland destruction, selenium repletion, gut healing, gluten elimination in sensitive individuals, stress management, and avoiding iodine excess. The earlier these interventions begin, the more thyroid tissue remains to preserve.

For a comprehensive approach, see our Hashimoto's natural treatment overview.

What's Still in the Pipeline (2026 and Beyond)

Three categories of research are worth tracking, though none are near clinical application for Hashimoto's.

Antigen-specific immunotherapy aims to tolerize the immune system to thyroid peroxidase and thyroglobulin, the specific proteins that Hashimoto's antibodies target. Rather than broadly suppressing immunity (like rituximab), this approach would teach the immune system to stop attacking thyroid tissue specifically. The research is in very early stages.

GLP-1 receptor agonists (semaglutide, tirzepatide) have documented anti-inflammatory effects through NF-kB suppression and T-cell modulation. The autoimmune data is accumulating across multiple conditions. Whether this translates to TPO antibody reduction in Hashimoto's is unknown; no thyroid-specific trial exists. For the current evidence on GLP-1 and autoimmunity, see GLP-1 for inflammation and autoimmune disease.

CAR-T cell therapy for autoimmune diseases made headlines when Mackensen et al. (2022, Nature Medicine) demonstrated complete remission in severe lupus using engineered T cells that targeted and depleted autoreactive B cells. The approach is being explored in other autoimmune conditions. For Hashimoto's, this is a theoretical future application. CAR-T carries significant risks (cytokine release syndrome, neurotoxicity) and costs ($300,000-500,000 per treatment). It would only be considered for severe, refractory autoimmune disease, not standard Hashimoto's.

Safety Checklist: Discuss With Your Endocrinologist

Before pursuing any treatment on this list, work through these considerations with your physician.

Before adding LDN: Confirm you are not taking any opioid medications. This is an absolute contraindication, non-negotiable. Inform your prescribing physician about all current medications.

Before adding metformin: Check kidney function (eGFR). Review current medications for interactions. Start with extended-release formulation to minimize GI side effects.

Selenium dosing: Do not exceed 200mcg per day. Selenosis (selenium toxicity) causes hair loss, nail brittleness, and GI symptoms that mimic the hypothyroid symptoms you are trying to treat. Get a baseline selenium level if possible.

Supplement and levothyroxine timing: Iron, calcium, and magnesium all impair levothyroxine absorption. Take these supplements at least 4 hours after your morning levothyroxine dose. See Hashimoto's supplements guide for a complete timing schedule.

Red light therapy: Ensure the provider is trained in photobiomodulation for thyroid application. Do not self-treat your thyroid with consumer LED panels. The thyroid requires specific wavelength, distance, and duration parameters that consumer devices do not provide.

Fasting protocols: Do not fast without medical supervision if you are underweight, pregnant, nursing, or have a history of eating disorders. Discuss medication timing during fasting days with your prescriber.

Frequently Asked Questions

Can Hashimoto's be cured in 2026?

No cure exists that permanently eliminates the autoimmune mechanism. But remission is real and documented. Spontaneous antibody normalization occurs in 5-20% of patients. Combinations of selenium, myo-inositol, dietary intervention, and immune modulation have normalized TPO antibodies in controlled trials. The accurate frame is "managed into remission," not "cured."

Can Hashimoto's go into remission?

Yes. Both spontaneous remission (5-20% of cases per Premawardhana et al. 2006) and treatment-induced remission have been documented. Early intervention, selenium repletion, gut healing, gluten elimination, and immune modulators like LDN improve the odds. Remission means stable TSH without medication, declining or normal TPO antibodies, and symptom resolution.

Is metformin a new treatment for Hashimoto's?

Metformin is a 60-year-old diabetes drug with an emerging thyroid application. Seventeen-plus studies now show it reduces TPO and TG antibodies in Hashimoto's patients. A 2023 meta-analysis in the Journal of Clinical Endocrinology & Metabolism (n=700+) confirmed significant antibody reduction versus controls. It is currently off-label for Hashimoto's.

What dose of LDN is used for Hashimoto's?

Standard protocol: start at 1.5mg nightly at bedtime, titrate to 3.0mg at 4-8 weeks, reach 4.5mg as the target maintenance dose if well tolerated. Some physicians start at 0.5-1.0mg for sensitive patients. LDN must be compounded by a specialty pharmacy. Cost is approximately $40-80 per 90-day supply.

Is red light therapy for Hashimoto's real?

One small but well-designed RCT (Höfling et al. 2012, n=43) showed near-infrared laser reduced levothyroxine requirements in 47% of patients and improved thyroid ultrasound findings. A 2025 review confirmed the signal across 8 studies. Evidence is Grade C: promising but preliminary.

What is the most promising new treatment available right now?

The selenium plus myo-inositol combination has the strongest RCT evidence for reducing TPO antibodies beyond what either supplement achieves alone. For off-label pharmacological options, LDN and metformin both carry Grade B evidence with growing clinical support. Your personalized protocol depends on your specific lab values, symptom severity, and current medication status.

This article was last updated March 2026. Treatments and evidence grades are current as of this date. New trial results may change these assessments.

Medical Disclaimer: This site provides educational information only. It is not medical advice. Always consult your healthcare provider before starting, stopping, or changing any treatment. The treatments discussed here are not substitutes for standard medical care. Work with a qualified endocrinologist for all Hashimoto's management decisions.